Genvor Inc

2023 Q2 Form 10-Q Financial Statement

#000149315223013379 Filed on April 24, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $100.00 $1.510K $86.46K
YoY Change
Cash & Equivalents $100.00 $1.513K $86.46K
Short-Term Investments
Other Short-Term Assets $1.500K $15.40K $15.40K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.600K $16.91K $101.9K
YoY Change -99.63% -80.99%
LONG-TERM ASSETS
Property, Plant & Equipment $16.19K $16.65K $17.11K
YoY Change -10.16% -9.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $16.19K $16.65K $17.11K
YoY Change -19.13% -103.19%
TOTAL ASSETS
Total Short-Term Assets $1.600K $16.91K $101.9K
Total Long-Term Assets $16.19K $16.65K $17.11K
Total Assets $17.79K $33.56K $119.0K
YoY Change -96.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $134.0K $302.3K $239.1K
YoY Change 833.13% 5396.36% 6731.43%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $48.75K $48.75K $48.75K
YoY Change
Long-Term Debt Due $1.180M $1.162M $1.132M
YoY Change
Total Short-Term Liabilities $1.845M $1.763M $1.670M
YoY Change 18.82% 4012.92% -31.83%
LONG-TERM LIABILITIES
Long-Term Debt $179.6K $149.4K $119.3K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $179.6K $149.4K $119.3K
YoY Change -65.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.845M $1.763M $1.670M
Total Long-Term Liabilities $179.6K $149.4K $119.3K
Total Liabilities $2.024M $1.913M $1.789M
YoY Change 8.54% -35.95%
SHAREHOLDERS EQUITY
Retained Earnings -$16.90M -$16.69M -$16.47M
YoY Change 7.15% 20828.96% 23512.68%
Common Stock $18.57K $18.42K $18.37K
YoY Change 6416.84% -7.89% -29.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.007M -$1.879M -$1.670M
YoY Change
Total Liabilities & Shareholders Equity $17.79K $33.56K $119.0K
YoY Change -96.09% -78.64%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 GNVR Issuance Of Common Stock For Services
IssuanceOfCommonStockForServices
usd
CY2022Q1 GNVR Fund Raising Services Amount
FundRaisingServicesAmount
usd
GNVR Late Fees
LateFees
60000 usd
CY2022Q4 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001792941
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Revenues
Revenues
usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2022Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-234815
dei Entity Registrant Name
EntityRegistrantName
GENVOR INCORPORATED
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2054746
dei Entity Address Address Line1
EntityAddressAddressLine1
13155 Noel Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 900
dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75240
dei City Area Code
CityAreaCode
(214)
dei Local Phone Number
LocalPhoneNumber
427-1921
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18422821 shares
CY2023Q1 us-gaap Cash
Cash
1513 usd
CY2022Q3 us-gaap Cash
Cash
296386 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
15397 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
16910 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
298386 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16650 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17565 usd
CY2023Q1 us-gaap Assets
Assets
33560 usd
CY2022Q3 us-gaap Assets
Assets
315951 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1162000 usd
CY2022Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1052000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
302295 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
516658 usd
CY2023Q1 GNVR Due To Related Party Current
DueToRelatedPartyCurrent
3846 usd
CY2022Q3 GNVR Due To Related Party Current
DueToRelatedPartyCurrent
3846 usd
CY2023Q1 us-gaap Loans Payable Current
LoansPayableCurrent
48750 usd
CY2022Q3 us-gaap Loans Payable Current
LoansPayableCurrent
48750 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
246400 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
246400 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1763291 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1867654 usd
CY2023Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
149444 usd
CY2022Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
89221 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
149444 usd
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
89221 usd
CY2023Q1 us-gaap Liabilities
Liabilities
1912735 usd
CY2022Q3 us-gaap Liabilities
Liabilities
1956875 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18422821 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18422821 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38678155 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38678155 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
18423 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
38678 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14789509 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14608815 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16689168 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16288417 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1879175 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1640924 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33560 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
315951 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
58858 usd
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
79505 usd
us-gaap Professional Fees
ProfessionalFees
65662 usd
us-gaap Professional Fees
ProfessionalFees
87758 usd
CY2023Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
37500 usd
CY2022Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
45725 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
75000 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
143225 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
102800 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
109248 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3010000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3210000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
458 usd
CY2022Q1 us-gaap Depreciation
Depreciation
458 usd
us-gaap Depreciation
Depreciation
916 usd
us-gaap Depreciation
Depreciation
916 usd
CY2023Q1 GNVR Other General And Administrative Expenses
OtherGeneralAndAdministrativeExpenses
58466 usd
CY2022Q1 GNVR Other General And Administrative Expenses
OtherGeneralAndAdministrativeExpenses
-36173 usd
GNVR Other General And Administrative Expenses
OtherGeneralAndAdministrativeExpenses
127286 usd
GNVR Other General And Administrative Expenses
OtherGeneralAndAdministrativeExpenses
104487 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
155282 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3202315 usd
us-gaap Operating Expenses
OperatingExpenses
268864 usd
us-gaap Operating Expenses
OperatingExpenses
3655634 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-155282 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3202315 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-268864 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3655634 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
5819 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
33230 usd
us-gaap Interest Expense
InterestExpense
11665 usd
us-gaap Interest Expense
InterestExpense
61002 usd
CY2023Q1 GNVR Penalties
Penalties
-30000 usd
CY2022Q1 GNVR Penalties
Penalties
-30000 usd
GNVR Penalties
Penalties
-60000 usd
GNVR Penalties
Penalties
-60000 usd
CY2023Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
30112 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
60223 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-65930 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-63230 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-131887 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-121002 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-221212 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3265545 usd
us-gaap Net Income Loss
NetIncomeLoss
-400751 usd
us-gaap Net Income Loss
NetIncomeLoss
-3776636 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18381710 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20449202 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20000000 shares
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-62540 usd
CY2021Q4 GNVR Recapitalization Rto Impact
RecapitalizationRtoImpact
-2382746 usd
CY2021Q4 GNVR Stockholders Equity Adjusted Balance
StockholdersEquityAdjustedBalance
-2445286 usd
CY2021Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
200000 usd
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1400 usd
CY2021Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
737510 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-511091 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2017467 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3010000 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
140000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
337573 usd
CY2022Q1 GNVR Payment For Reverses Capitalization
PaymentForReversesCapitalization
-150000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3265545 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-1945439 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1640924 usd
CY2022Q4 GNVR Stock Issued During Period Value Sale Of Common Stock
StockIssuedDuringPeriodValueSaleOfCommonStock
150000 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-179539 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1670463 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1670463 usd
CY2023Q1 GNVR Stock Issued During Period Value Sale Of Common Stock
StockIssuedDuringPeriodValueSaleOfCommonStock
12500 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-221212 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1879175 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1879175 usd
us-gaap Net Income Loss
NetIncomeLoss
-400751 usd
us-gaap Net Income Loss
NetIncomeLoss
-3776636 usd
us-gaap Depreciation
Depreciation
916 usd
us-gaap Depreciation
Depreciation
916 usd
GNVR Late Fee Capitalized Into Notes Payable
LateFeeCapitalizedIntoNotesPayable
60000 usd
GNVR Late Fee Capitalized Into Notes Payable
LateFeeCapitalizedIntoNotesPayable
60000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3210000 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
60223 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-496 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
13397 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-55665 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-214364 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-248543 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2800 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-507373 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-695302 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
50000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
34375 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1400 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
162500 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
877510 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
212500 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
913285 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-294873 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
217983 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
296386 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7310 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1513 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
225293 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16689168 usd
us-gaap Profit Loss
ProfitLoss
400751 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-507373 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_za3M9osmfypg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zqSHvqosAtCe">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
0 usd
CY2022Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
46386 usd
CY2023Q1 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P7Y
GNVR Late Fees
LateFees
60000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
109248 usd
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1462000 usd
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1460000 shares
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
150556 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
1311444 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
71665 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
121002 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
18144112 shares
CY2022Q2 GNVR Common Stock Retaining Share Value
CommonStockRetainingShareValue
1855888 shares
CY2023Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
2667462 usd
CY2022Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
2572885 usd
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-84158 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-204559 usd
us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-10420 usd
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-25326 usd
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
94577 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
229885 usd
CY2023Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2667462 usd
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2572885 usd
CY2023Q1 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2667462 usd
CY2022Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2572885 usd
CY2023Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2667462 usd
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2572885 usd
CY2023Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2667462 usd
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2572885 usd
CY2023Q1 us-gaap Assets Held In Trust
AssetsHeldInTrust
19705 usd
CY2022Q3 us-gaap Assets Held In Trust
AssetsHeldInTrust
19705 usd
CY2021Q4 us-gaap Payments For Rent
PaymentsForRent
2810 usd
us-gaap Payments For Rent
PaymentsForRent
6590 usd
us-gaap Payments For Rent
PaymentsForRent
20607 usd

Files In Submission

Name View Source Status
gnvr-20230331_cal.xml Edgar Link unprocessable
0001493152-23-013379-index-headers.html Edgar Link pending
0001493152-23-013379-index.html Edgar Link pending
0001493152-23-013379.txt Edgar Link pending
0001493152-23-013379-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
gnvr-20230331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
gnvr-20230331_def.xml Edgar Link unprocessable
gnvr-20230331_pre.xml Edgar Link unprocessable
gnvr-20230331_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable